Etemad-Moghadam Shahroo, Alaeddini Mojgan
Dental Research Center, Dentistry Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
J Oral Biol Craniofac Res. 2017 Jan-Apr;7(1):23-26. doi: 10.1016/j.jobcr.2016.11.001. Epub 2016 Nov 10.
Expression of various cellular/molecular factors change during the course of tumor formation from odontogenic tissues of the tooth germ. Evaluation of these factors can help provide a better perception of the tumorigenesis and biologic behavior of odontogenic tumors (OTs). Syndecan-1 is a heparan sulfate proteoglycan which has not been extensively investigated in these lesions. The objective of the present study was to assess the immunohistochemical expression of CD138 in adenomatoid odontogenic tumor (AOT), ameloblastic fibroma (AF) and odontogenic myxoma (OM) and to compare it with ameloblastoma and keratocystic odontogenic tumor (KCOT).
A total of 58 OTs consisting of 7 AOTs, 5 OMs, 7 AFs, 29 KCOTs and 10 ameloblastomas were immunohistochemically stained with monoclonal antibody against syndecan-1 and the percentage and intensity of the immunostained cells was assessed. Kruskal-Wallis test followed by Bonferroni analysis was used for comparisons ( < 0.05).
Syndecan-1 was expressed in all samples except for OMs. Both percentage and intensity of syndecan-1 expression were statistically different among the studied OTs ( < 0.001). Pairwise comparisons showed significant difference only between OMs and each of the other tumors.
Syndecan-1 may be involved in the pathogenesis of AOT, AF, KCOT and ameloblastoma. However, considering the different behaviors of these tumors along with their similar expression of syndecan-1, it seems that its effect on clinical aggressiveness is limited. The significance of negative immunoexpression of this protein in OM requires further investigation.
在牙胚的牙源性组织肿瘤形成过程中,各种细胞/分子因子的表达会发生变化。对这些因子的评估有助于更好地了解牙源性肿瘤(OTs)的肿瘤发生和生物学行为。Syndecan-1是一种硫酸乙酰肝素蛋白聚糖,在这些病变中尚未得到广泛研究。本研究的目的是评估CD138在腺样牙源性肿瘤(AOT)、成釉细胞纤维瘤(AF)和牙源性黏液瘤(OM)中的免疫组化表达,并将其与成釉细胞瘤和牙源性角化囊性瘤(KCOT)进行比较。
总共58例OTs,包括7例AOT、5例OM、7例AF、29例KCOT和10例成釉细胞瘤,用抗Syndecan-1单克隆抗体进行免疫组化染色,并评估免疫染色细胞的百分比和强度。采用Kruskal-Wallis检验,随后进行Bonferroni分析进行比较(P<0.05)。
除OM外,所有样本均表达Syndecan-1。在所研究的OTs中,Syndecan-1表达的百分比和强度在统计学上均有差异(P<0.001)。两两比较显示,仅OM与其他每种肿瘤之间存在显著差异。
Syndecan-1可能参与AOT、AF、KCOT和成釉细胞瘤的发病机制。然而,考虑到这些肿瘤的不同行为以及它们相似的Syndecan-1表达,似乎其对临床侵袭性的影响有限。该蛋白在OM中免疫表达阴性的意义需要进一步研究。